Literature DB >> 6109586

Triazolam disposition.

F S Eberts, Y Philopoulos, L M Reineke, R W Vliek.   

Abstract

Triazolam (T) is a new, potent hypnotic with a short duration of action in man. After an 0.88-mg oral dose of T-14C in six male subjects, mean recovery of 14C radioactivity was 85% in urine and 8% in feces. The major urinary metabolites were alpha-hydroxytriazolam (alpha-HT) and 4-hydroxytriazolam (4-HT), accounting for 69% and 11% of the urinary 14C, and these were mostly in conjugated form. alpha, 4-Dihydroxytriazolam and three dichlorotriazolylbenzophenone analogs were minor metabolites. At least 85% of the dose was rapidly absorbed; mean absorption half-life (t1/2A) was 2.8 min. After reaching a mean peak plasma level (Cmax) of 8.8 ng/ml at mean time (tmax) of 1.3 hr, plasma T decreased rapidly with a mean elimination half-life (t1/2E) of 2.3 hr. The remainder of the plasma 14C consisted predominantly of glucuronides of alpha-HT and 4-HT. Mean plasma parameters for these metabolites were as follows: alpha-HT-glucuronide, t1/2E = 3.9 hr, tmax = 1.3 hr, Cmax = 6.1 ng/ml; 4-HT-glucuronide, t1/2E = 3.8 hr, tmax = 2.5 hr, Cmax = 6.1 ng/ml. Nonconjugated alpha-HT and 4-HT were present in plasma but in insufficient amounts for kinetic analysis. The results are consistent with the short duration of action.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6109586     DOI: 10.1038/clpt.1981.14

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  34 in total

1.  Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.

Authors:  S Kanamitsu; K Ito; C E Green; C A Tyson; N Shimada; Y Sugiyama
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

Review 2.  Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

4.  Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration.

Authors:  G Roncari; W H Ziegler; T W Guentert
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

5.  Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects.

Authors:  R Jochemsen; J G Wesselman; C J van Boxtel; J Hermans; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

6.  Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.

Authors:  P D Kroboth; R B Smith; M R Silver; R Rault; M I Sorkin; J B Puschett; R P Juhl
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

Review 7.  Triazolam: a review of its pharmacological properties and therapeutic efficacy in patients with insomnia.

Authors:  G E Pakes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

8.  Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. II. Triazolam.

Authors:  S K Gupta; E H Ellinwood; A M Nikaido; D G Heatherly
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

9.  Dose equivalence of midazolam and triazolam. A psychometric study based on flicker sensitivity, reaction time and digit symbol substitution test.

Authors:  H J Sostmann; H Sostmann; C Crevoisier; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

10.  The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; R B Smith; R I Shader
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.